ORIC Stock Analysis: Buy, Sell, or Hold?
ORIC - Oric Pharmaceuticals, Inc. Common Stock
$10.60
-0.47 (-4.25%)
▼
5d:
-11.81%
30d:
-8.93%
90d:
+8.5%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
6d
Smart Money Accumulation
None View Scanner →
Strength: 4.8/10
Get Alerted When ORIC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ORIC is down 11.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ORIC is down 11.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ORIC is currently trading at $10.60, which is considered fair relative to its 30-day fair value range of $10.28 to $11.51.
Technical Outlook: Technically, ORIC is showing sideways momentum. The price is currently testing key support at $10.37. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.69 (+95.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ORIC is showing sideways momentum. The price is currently testing key support at $10.37. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.69 (+95.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$10.28 -
$11.51
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.2%)
- BULLISH: Trading 95.2% below Wall St target ($20.69)
- WARNING: Recommendation downgraded due to -11.8% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$10.28 -
$11.51
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$10.37
Resistance Level
$12.57
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.57
Wall Street Target
$20.69
(+95.2%)
Share & Embed Analysis
Last updated: August 03, 2026 7:53 PM ET
Data refreshes hourly during market hours. Next update: 8:53 PM
Data refreshes hourly during market hours. Next update: 8:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORIC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Dominic Piscitelli
SELL
52000 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 46 HOLD |
